"Absence of Effect of Zidovudine on Replication of Hepatitis B Virus in" Patients with Chronic HIV and HBV Infection

Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

"Absence of Effect of Zidovudine on Replication of Hepatitis B Virus in" Patients with Chronic HIV and HBV Infection

New England Journal of Medicine (12/21/89) Vol. 321, No. 25, P. 1758
Marcellin, Patrick, et al.

Abstract: AZT used alone appears to have no therapeutic value in the treatment of chronic hepatitis B, write Patrick Marcellin and fellow researchers at Hopital Beaujon, Clichy, France. The researchers report on a study of 15 men with HIV-1 and chronic hepatitis B virus (HBV) infection who had been taking AZT for a mean period of 39 weeks at the time of analysis. The results of the study suggest that AZT in doses of 600 mg to 1200 mg has no significant effect on the serum levels of HBV DNA in patients with chronic HIV and HBV infections. Because most of the patients had AIDS or ARC, the researchers say, they can't rule out an inhibitory effect of AZT on HBV replication in asymptomatic anti-HIV-positive or anti-HIV-negative subjects. In addition, Marcellin and colleagues point out, AZT in association with alpha interferon or another anti-viral compound might have a synergistic effect on HBV.

891221
AD890036

Copyright © 1989 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.